Introduction
C3 glomerulopathy (C3G) is a recently defined pathological entity charac terized by C3 accumulation with absent or scant immunoglobulin deposition leading to variable glomerular inflammations 1, 2) . C3G was often diagnosed previously as membranoproliferative glomerulonephritis (MPGN) because of similarities in the light microscopy (LM) and electron microscopy (EM) findings. MPGN can be classified into either immunoglobulin (IgG) associated MPGN (caused by classical complement pathway activation); MPGN with dominant C3 (C3G and C3GN); or idiopathic MPGN. Both C3GN and idiopathic MPGN are caused by alternative complement pathway activations 3) . C3G includes C3 glomerulonephritis (C3GN) and dense deposit disease (DDD) 4, 5) . The difference between C3GN and DDD is that DDD is charac terized by the presence of extremely electrondense deposits in the basement membrane, while the changes observed in patients with C3GN are more heterogenous. C3GN also includes disease entities associated with complement mutation, which is causally associated with the underlying renal pathology, such as familial DDD with C3 mutation and familial C3GN with mutations in the CFHR genes. The incidence of C3GN is reported to be one to two per 1,000,000 children, with its onset occurring between 5 and 15 years of age. The clinical manifestations of C3GN comprise a wide spectrum, in cluding mild urinary abnormalities, nephrotic syndrome, and nephritic syndrome with or without renal impairment 1, 3, 6, 7) . The condition often progresses to chronic kidney dis ease or endstage kidney disease and can recur after renal transplantation.
In affected patients, the alternative pathway produces C3 convertase, which amplifies C3 activation, resulting in the creation of C3b particles, and finally, the formation of C5 convertase to assemble MAC C5b9. This damages the cells via the development of a lytic pore and leads to cellular death via apoptosis or necrosis. Factor H and other comple ment proteins regulate the amplification of C3 activation 8) .
The current treatment includes supportive measures and use of immunosuppressants, including prednisone, mycophenolate mofetil (MMF), and calcineurin inhibitors. Recently, plasma exchange/plasma infusion and provision of eculizumab, a monoclonal antibody against C5, can be used in cases of nephritic syndrome and/or decreased renal function in patients with C3GN.
Case report
Proteinuria and microscopic hematuria were first de tected via a school urinary screening in a 10yearold girl. The patient was referred to our hospital for evaluation by a local hospital. Her physical examination findings were normal, there was also no edema. The patient had a normal blood pressure of 100/60 mmHg. The laboratory investiga tion results upon admission were as follows: leukocyte count, 9,170/µL; platelet count, 460 K/µL; hemoglobin level, 12.8 g/dL; BUN level, 11.9 mg/dL; and serum creatinine level, 0.7 mg/dL (eGFR, 94.7 mL/min/1.73 m 2 , Schwarz formula). Urinalysis showed only microscopic hematuria (RBC count, 2030/HPF) by dipstick, and the level of pro tein identified in the 24hour urine study was 47 mg/m 2 / day. A markedly decreased C3 level of 15 mg/dL (reference range: 77195 mg/dL) and normal C4 level of 15.9 mg/dL (reference range: 740 mg/dL) were noted on immunolo gical evaluation. The infectious serology tests conducted for hepatitis B and hepatitis C revealed negative findings. Renal imaging showed that the patient had normalsized kidneys, with ureteral duplication. Renal biopsy was per formed owing to persistently decreased C3 level. LM showed diffuse exudative proliferative glomerulonephritis. On im munofluorescence staining, a markedly increased granular deposit of C3 in the mesangium was noted without any other immunoglobulin deposition. EM revealed an elec trondense deposit along the glomerular basement mem brane. We initiated the administration of angiotensin converting enzyme (ACE) inhibitors for supportive care. The patient showed only microscopic hematuria and de creased serum C3 level without proteinuria for 3 years. However, we subsequently failed to follow up with the pa tient, and after 2 years, the patient revisited our hospital with nephroticrange proteinuria (53.37 mg/m 2 /h) and microscopic hematuria with normal renal function at the age of 15 years. She reported no symptoms during the en tire period. A second biopsy was performed, which showed an MPGN pattern with predominant C3 deposits on im munofluorescence staining, similar to those observed on the first biopsy ( Fig. 1) . At this time, the patient's levels of complement factor H, factor B, and antiCFH autoantibody were within normal ranges. However, the level of complement factor I (CFI) decreased to 0.47 mg/dL, as compared with the reference value (3.85.8 mg/dL). There was no mutation of CFI by Sanger sequencing noted. During the genetic study for the alternative pathway of the complement system, a heterozy gous mutation was detected in a C8A gene mutation known to be associated with atypical hemolytic uremic syndrome (aHUS) or DDD. However, the C8α plasma level and he molytic activity were needed to confirm the presence of a meaningful mutation of the C8A gene.
We started to administer ACE inhibitors and angiotensin receptor blockers (ARBs) to reduce the proteinuria. There after, the amount of proteinuria was decreased with these treatments; however, after 8 months, proteinuria was inc www.chikd.org reased to 95 mg/m 2 /h. At that time, it was decided that we could not use eculizumab because it was expensive; thus, we added oral prednisolone (40 mg/day) and MMF (1 g/day). Following prescription, proteinuria was decreased to UPr/ cr of 0.4; however, proteinuria was sustained with a consis tently low serum C3 level (10.8 mg/dL, reference range: 77 195 mg/dL). MMF was replaced with cyclosporine. It was also determined that we could not use prednisolone for longterm maintenance because the patient demonstrated a cushingoid appearance and amenorrhea. Thus, we tapered off the dosage of prednisolone and decided only to use cy closporine and an ACE inhibitor for maintenance. After 6 months, the patient's proteinuria had improved, and her serum C3 level recovered back to normal (106 mg/dL, re ference range: 77195 mg/dL). We continued to administer cyclosporine and ACE inhibitor; thereafter, we attempted to taper off the dosage of cyclosporine. However, when we reduced the dosage of cyclosporine, her proteinuria wor sened; hence, we continued to administer cyclosporine (150 mg/day) and ACE inhibitor (Fig. 2) . 
Discussion
We reported a case of C3GN detected via school urine examination in a 10yearold girl, which was confirmed via renal biopsy and showed a membranoproliferative pattern with electrondense deposits on the subendothelium and interstitial fibrosis. A low serum C3 level is commonly ob served in patients with this disease, but does not correlate with the severity of the condition 9) . The prognosis of these patients may be determined by a decrease in the eGFR and the severity of proteinuria at the time of diagnosis and du ring followup as in most renal diseases 10) . The degree of tu bulointerstitial fibrosis is another poor prognostic factor, more so than the severity of glomerular changes 11) . There is no consensus regarding recommendation of a specific treat ment in children with C3GN. There is also no evidence for the treatment with ACE inhibitors or ARBs. However, these medications should only be considered for use because of the existing ability to extrapolate information from other proteinuric renal diseases. The limited data on the use of ACE inhibitors or ARBs in patients with C3GN had been reported in a French C3G cohort, where it was stated that treatment with ACE inhibitors or ARBs might improve renal survival (P<0.0001) 12) . Some studies have reported that anticellular immune suppression is considered less effective in children with C3GN. Servais et al. reported that immunosuppressants were not associated with renal survival 12) . Another previous study reported the failure of treatment with glucocorticoids in helping patients achieve remission after 5 years 13) . However, recent case series suggested that the admini stration of MMF is effective 14, 15) . Furthermore, a recent KDIGO (Kidney Disease: Improving Global Outcomes) controversies conference recommended that C3G patients with moderate disease (defined as urine protein of more than 500 mg/24 hours or recent rise in creatinine or mode rate inflammation on renal biopsy) despite supportive the rapy receive prednisone or MMF 16) . There are also reports for the effectiveness of cyclosporin in patients with C3G. Bagheri et al. noted that 18 patients with MPGN who were treated with cyclosporine showed an excellent response to the medication 17) . Recently, new therapies have been suggested to target complement pathways owing to an improvement in the understanding of the pathogenesis of C3GN. An anticom plement effect for C3G has been predicted via the use of an animal model 18) . C3G complement blockade eculizumab is a monoclonal antibody targeted against complement C5 that inhibits the activation of the alternative complement pathway. Although reported results to date are conflicting, many studies have reported an efficacy of eculizumab in patients with C3G, even in children 18, 19) . Eculizumab is ap proved by the United States Food and Drug Administration for the treatment of aHUS, thrombotic microangiopathy, and paroxysmal nocturnal hemoglobinuria. Therefore, it is used as an offlabel medication for C3G.
As mentioned above, recently conducted studies explain the effectiveness of eculizumab because of the understan ding of the pathogenesis of C3G. However, eculizumab cannot be used in some instances, and in these instances, it has been reported that cyclosporine is effective for ma naging steroidresistant nephrotic syndrome caused by MPGN II 2022) . Our patient was partially responsive to MMF treatment but had persistent proteinuria and a low serum C3 level. When we switched MMF to cyclosporine, her pro teinuria resolved, and the serum C3 level also normalized. Therefore, we reported a case of C3GN successfully treated with cyclosporine. We suggest that cyclosporine be con sidered as a therapeutic agent for C3GN in cases in which eculizumab cannot be used and/or if the patient does not respond to other immunosuppressants, such as steroids and MMF.
